decibel therapeutics hearing loss drug license oricula

Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics

BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…

Read More
tinnitus drug pharma hearing loss

FDA Fast Tracks Tinnitus Drug; Meniere’s Drug Completes Year-Long Safety Trial

ZUG, SWITZERLAND — Biopharmaceutical company Auris Medical Holdings announced late last month that the US Food and Drug Administration (FDA) granted Fast Track designation to its investigational drug, KeyzilenTM (AM-101).  Keyzilen is esketamine gel for intratympanic injection, intended for acute peripheral tinnitus following cochlear injury or otitis media in adults.  The Fast Track designation by the FDA of an…

Read More
inner ear

Biotech Startup Receives $2M NIH Grant for Drug Development to Prevent Antibiotic-Related Hearing Loss

SEATTLE, WASHINGTON — Oricula Therapeutics, LLC, a biotech startup firm based in Seattle, announced today that it has received a Phase 2 Grant of approximately $2 million dollars from the Small Business Innovation Research (SBIR) program through the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). The award funds will support…

Read More